Valitor has developed novel methods of modifying therapeutic proteins to achieve substantial control over their pharmacological properties..
Valitor has raised $28.0M in total funding. The most recent round was Series B. The last funding was announced in October 2022.
Valitor's investors include SkyDeck Berkeley, First Spark Ventures, Berkeley SkyDeck Fund, Berkeley Catalyst Fund (BCF), ExSight Ventures.
Valitor is headquartered in Berkeley, United States.
Valitor has developed novel methods of modifying therapeutic proteins to achieve substantial control over their pharmacological properties..
Valitor is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Valitor — Funding & Investors." VCBacked, October 5, 2022, https://www.vcbacked.co/company/valitor. Accessed August 14, 2026.
VCBacked. (2022). Valitor — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/valitor
{{cite web |title=Valitor — Funding & Investors |url=https://www.vcbacked.co/company/valitor |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated